Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (Q37026026)
Jump to navigation
Jump to search
scientific article published on 15 March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase |
scientific article published on 15 March 2013 |
Statements
1 reference
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (English)
1 reference
Hagop M Kantarjian
1 reference
Gianantonio Rosti
1 reference
Yaping Shou
1 reference
Matt E Kalaycio
1 reference
Carmino De Souza
1 reference
Albert Hoenekopp
1 reference
Dong-Wook Kim
1 reference
Gabriel Etienne
1 reference
Mineo Kurokawa
1 reference
Xiaolin Fan
1 reference
Timothy P Hughes
1 reference
Identifiers
1 reference